The Healthcare Supply Chain Association (HSCA) today announced its
support for the “Increasing Competition in Pharmaceuticals Act” (S.2615), new legislation from Senators Susan
Collins (R-ME) and Claire McCaskill (D-MO) aimed at creating a more competitive
generic drug marketplace.
“The Increasing
Competition in Pharmaceuticals Act (S.2615) is an important step toward
fostering a more competitive generic drug marketplace and ensuring patient
access to affordable medications,” said HSCA President and CEO Todd
Ebert, R.Ph. “HSCA applauds Senators Collins and McCaskill for their leadership
on S.2615 and we support the legislation’s mandated priority review of abbreviated new drug applications (ANDAs) for generic
drugs made by just one manufacturer. Healthcare group purchasing organizations
have a unique line of sight on the healthcare supply chain, and we look forward
to continuing to serve as a resource to the Senate Special Committee on Aging
as they work to advance S.2615.”
HSCA confirmed its support for the “Increasing Competition in
Pharmaceuticals Act” in a letter to the Chair and Ranking Member of the Senate
Special Committee on Aging, which also thanked the Senators for their ongoing work to reduce healthcare costs and safeguard
patient and provider access to generic drugs. The letter went on to encourage
the Committee to consider future enhancements to the legislation, in the form
of a new subsection that also mandates priority review for generic injectable
drugs with two or fewer manufacturers.